ANGLE PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.94 GBX | +6.75% |
|
+24.54% | +27.19% |
| Apr. 24 | No record close for FTSE 100; mixed trade in US | AN |
| Apr. 24 | No record close for FTSE 100; mixed trade in US | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ANGLE plc is a United Kingdom-based liquid biopsy company. The Company is engaged in the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy-non-invasive cancer diagnostics. Its platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for highly multiplexed analysis of nucleic acids and proteins. Its Parsortix PC1 Clinical system captures and harvests circulating CTCs from metastatic breast cancer patients blood for subsequent, user-validated analysis. The Parsortix PC1 Clinical System is a liquid biopsy technology. Its labs in Guildford provide specialist CTC enrichment and analysis services to support translational research studies and pharmaceutical trials. It has developed the Parsortix system, including instruments and one-time use cassettes that can be sold to third-party laboratories for their use in research, pharmaceutical development, or clinical use.
Calendar
2024-06-25
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.14
GBP
Average target price
0.685
GBP
Spread / Average Target
+389.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.19% | 45.56M | |
| -13.00% | 18.55B | |
| -46.15% | 2.65B | |
| +14.09% | 1.81B | |
| -3.39% | 1.61B | |
| +21.69% | 1.21B | |
| -10.58% | 1.03B | |
| -21.72% | 896M | |
| -7.58% | 680M | |
| -17.56% | 686M |
- Stock Market
- Equities
- AGL Stock
- News ANGLE plc
- Angle : Shares Jump 6% On Securing New Pharma Contract
